Clinical Trials Drug Efficacy Efficacy Studies Drug Trials Randomized Controlled Trials Drug Development Psychedelic Research Pharmacology Drug Studies Evidence-Based Medicine AI Applications Psychedelic Studies Cancer Therapy Development Real-World Evidence Implant Studies Psychological Therapies Trial Design Neuroscience Drug Formulations Ophthalmology Pilot Studies Quantitative Studies Real-World Data Trial Applications Medical Curriculum Weight Loss Studies Medical Research Systematic Reviews Trial Results Women's Health Initiative Pediatric Studies Pharmacokinetics Trials Medical Studies Psychiatric Interventions Therapeutic Benefits of MDMA Psychiatric Studies Pharmacovigilance COVID-19 Impact Drug Safety Phase Trials Study Findings Epidemiology Study Design
The decision follows Phase 3 MajesTEC-3 results that showed an 83% lower risk of progression or death versus daratumumab-based regimens.
